These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 38184323

  • 1. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
    Greene SJ, Butler J, Kosiborod MN.
    Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
    [Abstract] [Full Text] [Related]

  • 2. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
    Wang Y, Gao T, Meng C, Li S, Bi L, Geng Y, Zhang P.
    Eur J Med Res; 2022 Dec 29; 27(1):314. PubMed ID: 36581880
    [Abstract] [Full Text] [Related]

  • 3. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B, Zhang R, Wu X, Zhou X.
    JAMA Netw Open; 2022 Sep 01; 5(9):e2231963. PubMed ID: 36125813
    [Abstract] [Full Text] [Related]

  • 4. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
    Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, Çavuşoğlu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferović J, Jhund PS, Dattilo G, Čelutkiene J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, de Boer RA, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainščak M, Jankowska E, Mueller C, Cosentino F, Lund L, Filippatos GS, Ruschitzka F, Coats AJS, Rosano GMC.
    Eur J Heart Fail; 2020 Sep 01; 22(9):1495-1503. PubMed ID: 32618086
    [Abstract] [Full Text] [Related]

  • 5. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
    Butler J, Handelsman Y, Bakris G, Verma S.
    Eur J Heart Fail; 2020 Apr 01; 22(4):604-617. PubMed ID: 31926059
    [Abstract] [Full Text] [Related]

  • 6. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
    Starr JA, Pinner NA.
    Ann Pharmacother; 2024 May 01; 58(5):506-513. PubMed ID: 37542422
    [Abstract] [Full Text] [Related]

  • 7. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S.
    Adv Ther; 2022 Feb 01; 39(2):845-861. PubMed ID: 34881413
    [Abstract] [Full Text] [Related]

  • 8. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
    Treewaree S, Kulthamrongsri N, Owattanapanich W, Krittayaphong R.
    Front Cardiovasc Med; 2023 Feb 01; 10():1046194. PubMed ID: 36824458
    [Abstract] [Full Text] [Related]

  • 9. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS, Correa A, Contreras JP.
    Eur Heart J Cardiovasc Pharmacother; 2022 May 05; 8(3):311-321. PubMed ID: 34264341
    [Abstract] [Full Text] [Related]

  • 10. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
    Starr JA, Pinner NA, Lisenby KM, Osmonson A.
    Pharmacotherapy; 2021 Jun 05; 41(6):526-536. PubMed ID: 33866578
    [Abstract] [Full Text] [Related]

  • 11. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M.
    Lancet; 2020 Sep 19; 396(10254):819-829. PubMed ID: 32877652
    [Abstract] [Full Text] [Related]

  • 12. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
    Brown E, Wilding JPH, Alam U, Barber TM, Karalliedde J, Cuthbertson DJ.
    Ann Med; 2021 Dec 19; 53(1):2072-2089. PubMed ID: 33107349
    [Abstract] [Full Text] [Related]

  • 13. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.
    Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M.
    Eur J Heart Fail; 2022 Mar 19; 24(3):431-441. PubMed ID: 34894038
    [Abstract] [Full Text] [Related]

  • 14. Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
    Cheng JWM, Colucci V, Kalus JS, Spinler SA.
    Ann Pharmacother; 2023 Nov 19; 57(11):1291-1301. PubMed ID: 36800904
    [Abstract] [Full Text] [Related]

  • 15. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F, Martins VM, Scheffel RS, da Silveira AD, Motta MT, Moriguchi EH, Santos RD, Stein R.
    Ann Pharmacother; 2021 Oct 19; 55(10):1267-1275. PubMed ID: 33401940
    [Abstract] [Full Text] [Related]

  • 16. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
    Karangelis D, Mazer CD, Stakos D, Tzifa A, Loggos S, Verma S, Mitropoulos F.
    Curr Pharm Des; 2021 Oct 19; 27(8):1051-1060. PubMed ID: 33143620
    [Abstract] [Full Text] [Related]

  • 17. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
    Jhund PS.
    Heart Fail Clin; 2022 Oct 19; 18(4):579-586. PubMed ID: 36216487
    [Abstract] [Full Text] [Related]

  • 18. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ, Brunton SA, Rangaswami J.
    Cardiovasc Diabetol; 2023 Nov 16; 22(1):316. PubMed ID: 37974185
    [Abstract] [Full Text] [Related]

  • 19. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
    Kotit S.
    Glob Cardiol Sci Pract; 2023 May 11; 2023(2):e202314. PubMed ID: 37351098
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.